Form D · Other
Yuva Biosciences, Inc.
Birmingham, AL · CIK 0001998258
Offering snapshot reported Mar 24, 2026 · SEC filing
- Reported sold
- $1.12M Offering amount: $3M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 16, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 24, 2026 | Initial | $1,118,000 | No comparison | 11 | SEC filing |
| Nov 7, 2023 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-577488
Simple Agreements for Future Equity (SAFEs) and equity securities of Issuer into which SAFEs may convert
Source: Form D, filed Mar 24, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daniel Browne | Director |
| Fred Ehrsam | Director |
| Greg Schmergel | Director, Executive |
Issuer details
Industry: Other (See others in industry)
Address:
1500 1 St Avenue N Suite L 133
Birmingham, AL, 35203
Birmingham, AL, 35203